GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Sai Parenterals Ltd

Sai Parenterals Reports Q2 FY27 Net Profit of Rs. 105.10 Million, Completes Saicriti Pharma Acquisition

RESULTS ▲ Positive Development MEDIUM RISK
📅 Filed on BSE: 01 Nov 2026, 04:04 PM IST  ·  BSE ID: 31caef74-b3b9-433d-b834-77a914de7877
View Original BSE Filing (PDF)
💡
In Simple Terms
The company announced its Q2 FY27 profit of Rs. 105.10 Million and finalized a key acquisition while planning another for a full takeover.
🤖 AI Summary
  • Sai Parenterals reported a consolidated net profit of Rs. 105.10 Million for Q2 FY27, ended September 30, 2026.
  • The company completed the acquisition of 60% equity share capital in Saicriti Pharma Private Limited.
  • Sai Parenterals will acquire the remaining 25% equity in SP Analytics Private Limited for Rs. 25,000/- by December 31, 2026.
  • Consolidated revenue from operations for Q2 FY27 stood at Rs. 194.01 Million.
  • A Management Committee was constituted for the company's smooth functioning and administration.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Profit After Tax (Q2 FY27)
105.10 Millions
65.51
Revenue from Operations (Q2 FY27)
194.01 Millions
262.46
Total Income (Q2 FY27)
198.63 Millions
262.06
Cost of Acquisition (SP Analytics)
25,000/-
Net Profit Before Tax (Half Year Ended 30.09.2026)
196.79 Millions
76.36
🏢 How This Affects the Company
📈
Business Impact
The completed acquisition of Saicriti Pharma Private Limited and planned full acquisition of SP Analytics Private Limited will expand the company's portfolio and operational capabilities in the pharma sector, particularly in testing and analysis.
💰
Financial Impact
Consolidated net profit reached Rs. 105.10 Million for Q2 FY27, with revenue from operations at Rs. 194.01 Million. The acquisition of SP Analytics is for a consideration of Rs. 25,000/- in cash.
⚙️
Operational Impact
The acquisitions make Saicriti Pharma a subsidiary and SP Analytics a wholly-owned subsidiary, integrating their operations. The new Management Committee aims to streamline internal functioning and administration.
⚠️
Risk Impact
The acquisition of SP Analytics is identified as a Related Party Transaction, with promoter/promoter group interest, though stated to be at arm’s length. SP Analytics reported nil turnover in the last three financial years, potentially indicating a greenfield or development-stage asset.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required by shareholders based on this specific filing.
👤
Who Is Affected
Shareholders of Sai Parenterals Ltd will see the company's financial results reflecting enhanced profitability for Q2 FY27 and expanded scope through completed and planned acquisitions, particularly those with a long-term view on the company's strategic growth initiatives.
🔍
Management Signal
The Board's decisions to approve financial results, complete a significant acquisition, and plan for a full subsidiary acquisition signal a focus on growth through inorganic expansion and strengthening internal governance with a new Management Committee.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Q3 FY27 results — monitor revenue and profit contribution from Saicriti Pharma.
Completion of SP Analytics acquisition — confirm full ownership by December 31, 2026.
Further details on Management Committee's impact on operational efficiency.
MEDIUM RISK Acquisition of SP Analytics is a related party transaction, and SP Analytics reported nil turnover for the last three years.
💡 Investor Takeaway
Sai Parenterals' consolidated net profit for Q2 FY27 rose to Rs. 105.10 Million from Rs. 63.50 Million in Q2 FY26, with revenue from operations at Rs. 194.01 Million. The company completed the acquisition of 60% in Saicriti Pharma and will fully acquire SP Analytics for Rs. 25,000/- by December 31, 2026.
⚖️ Strengths & Concerns

✅ Positives

  • Consolidated Profit After Tax for Q2 FY27 increased to Rs. 105.10 Million from Rs. 63.50 Million in Q2 FY26.
  • Completion of 60% equity acquisition in Saicriti Pharma Private Limited enhances the company's market presence and capabilities.

⚠️ Concerns

  • SP Analytics Private Limited, being fully acquired, reported nil turnover during the last three financial years, indicating no operational revenue contribution.
  • Total current liabilities stood at Rs. 4,640.97 Million as of September 30, 2026, against total current assets of Rs. 6,349.59 Million.
📅 Company Track Record
Sai Parenterals has been actively pursuing strategic growth, as evidenced by its previous Q2 FY27 results filing on the same date, which also noted the completion of Saicriti Pharma acquisition. The company's board meetings consistently address financial results and strategic corporate actions.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What is Sai Parenterals' consolidated net profit for Q2 FY27?
Sai Parenterals reported a consolidated net profit of Rs. 105.10 Million for the quarter ended September 30, 2026 (Q2 FY27).
What was Sai Parenterals' consolidated revenue from operations in Q2 FY27?
Consolidated revenue from operations for Sai Parenterals was Rs. 194.01 Million for the quarter ended September 30, 2026 (Q2 FY27).
Which acquisition did Sai Parenterals complete as per the filing?
Sai Parenterals completed the acquisition of 60% of the equity share capital of Saicriti Pharma Private Limited, making it a subsidiary.
What are Sai Parenterals' plans for SP Analytics Private Limited?
Sai Parenterals plans to acquire the remaining 25% equity shareholding in SP Analytics Private Limited for Rs. 25,000/- by December 31, 2026, making it a wholly-owned subsidiary.
What was the Profit Before Tax for Sai Parenterals for the half year ended September 30, 2026?
The consolidated Profit Before Tax for Sai Parenterals for the half year ended September 30, 2026, was Rs. 196.79 Million.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again — explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.